Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2359)
All Articles published online
|
Nov 15, 2003 (publication date) through Jun 4, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chen XP, He SQ, Wang HP, Zhao YZ, Zhang WG. Expression of TNF-related apoptosis-inducing Ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing Ligand in human hepatocellular carcinoma. World J Gastroenterol 2003; 9(11): 2433-2440 [PMID: 14606071 DOI: 10.3748/wjg.v9.i11.2433] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v9/i11/2433.htm |
| Number | Citing Articles |
| 1 |
Andres Forero-Torres, Katherine E. Varley, Vandana G. Abramson, Yufeng Li, Christos Vaklavas, Nancy U. Lin, Minetta C. Liu, Hope S. Rugo, Rita Nanda, Anna M. Storniolo, Tiffany A. Traina, Sujata Patil, Catherine H. Van Poznak, Julie R. Nangia, William J. Irvin, Helen Krontiras, Jennifer F. De Los Santos, Paul Haluska, William Grizzle, Richard M. Myers, Antonio C. Wolff. TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research 2015; 21(12): 2722 doi: 10.1158/1078-0432.CCR-14-2780
|
| 2 |
Guan Wang, Yao Zhan, Haiqing Wang, Wenhua Li. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein. Cancer Chemotherapy and Pharmacology 2012; 69(3): 799 doi: 10.1007/s00280-011-1763-0
|
| 3 |
Henning Walczak, Ronald Koschny, Daniela Willen, Manuela B. Schader, Jaromir Sykora, Tom M. Ganten, Tobias L. Haas. Apoptosis and Cancer Therapy. 2006; : 31 doi: 10.1002/9783527619665.ch2
|
| 4 |
EW Duiker, ECF Dijkers, H Lambers Heerspink, S de Jong, AGJ van der Zee, PL Jager, JGW Kosterink, EGE de Vries, MN Lub‐de Hooge. Development of a radioiodinated apoptosis–inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies. British Journal of Pharmacology 2012; 165(7): 2203 doi: 10.1111/j.1476-5381.2011.01718.x
|
| 5 |
Hiroki Matsubara, Yoichi Mizutani, Fumiya Hongo, Hiroyuki Nakanishi, Yasunori Kimura, So Ushijima, Akihiro Kawauchi, Takahiro Tamura, Tsuneaki Sakata, Tsuneharu Miki. Gene therapy with TRAIL against renal cell carcinoma. Molecular Cancer Therapeutics 2006; 5(9): 2165 doi: 10.1158/1535-7163.MCT-05-0522
|
| 6 |
J CORMIER, K THOMAS, R CHARI, C PINSON. Management of Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery 2006; 10(5): 761 doi: 10.1016/j.gassur.2005.10.006
|
| 7 |
Kenichi Harada, Yasunori Sato, Keita Itatsu, Kumiko Isse, Hiroko Ikeda, Mitsue Yasoshima, Yoh Zen, Akira Matsui, Yasuni Nakanuma. Innate immune response to double-stranded RNA in biliary epithelial cells is associated with the pathogenesis of biliary atresia. Hepatology 2007; 46(4): 1146 doi: 10.1002/hep.21797
|
| 8 |
Tom M. Ganten, Jaromir Sykora, Ronald Koschny, Emanuela Batke, Sebastian Aulmann, Ulrich Mansmann, Wolfgang Stremmel, Hans-Peter Sinn, Henning Walczak. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. Journal of Molecular Medicine 2009; 87(10): 995 doi: 10.1007/s00109-009-0510-z
|
| 9 |
Juan Yang, Guiyuan Li, Keqiang Zhang. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer. Biomedicine & Pharmacotherapy 2016; 84: 1078 doi: 10.1016/j.biopha.2016.10.028
|
| 10 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2017; : 3217 doi: 10.1007/978-3-319-26956-6_176
|
| 11 |
Sundas Fayyaz, Ilhan Yaylim, Saime Turan, Sobia Kanwal, Ammad Ahmad Farooqi. Hepatocellular carcinoma: targeting of oncogenic signaling networks in TRAIL resistant cancer cells. Molecular Biology Reports 2014; 41(10): 6909 doi: 10.1007/s11033-014-3577-8
|
| 12 |
Isabel Fabregat. Dysregulation of apoptosis in hepatocellular carcinoma cells. World Journal of Gastroenterology 2009; 15(5): 513-520 doi: 10.3748/wjg.15.513
|
| 13 |
Hong Ma, Yanxin Liu, Shilian Liu, Ruian Xu, Dexian Zheng. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology 2005; 42(6): 1355 doi: 10.1002/hep.20918
|
| 14 |
Thomas Tu, Magdalena A. Budzinska, Nicholas A. Shackel, Allison R. Jilbert. Conceptual models for the initiation of hepatitis B virus‐associated hepatocellular carcinoma. Liver International 2015; 35(7): 1786 doi: 10.1111/liv.12773
|
| 15 |
Meng-Sen Li, Ping-Feng Li, Qian Chen, Guo-Guang Du, Gang Li. Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells. World Journal of Gastroenterology 2004; 10(6): 819-824 doi: 10.3748/wjg.v10.i6.819
|
| 16 |
Robin C. Humphreys, Wendy Halpern. Programmed Cell Death in Cancer Progression and Therapy. Advances in Experimental Medicine and Biology 2008; 615: 127 doi: 10.1007/978-1-4020-6554-5_7
|
| 17 |
Chen-Yi Liao, Ching-Chang Lee, Chi-chang Tsai, Chao-Wen Hsueh, Chih-Chiang Wang, I-Hung Chen, Ming-Kai Tsai, Mei-Yu Liu, An-Tie Hsieh, Kuan-Jen Su, Hau-Ming Wu, Shih-Chung Huang, Yi-Chen Wang, Chien-Yao Wang, Shu-Fang Huang, Yen-Cheng Yeh, Ren-Jy Ben, Shang-Tao Chien, Chin-Wen Hsu, Wu-Hsien Kuo. Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma. BioMed Research International 2015; 2015: 1 doi: 10.1155/2015/840542
|
| 18 |
Lydia Kriegl, Andreas Jung, Jutta Engel, Rene Jackstadt, Alexander L. Gerbes, Eike Gallmeier, Jana A. Reiche, Heiko Hermeking, Antonia Rizzani, Christiane J. Bruns, Frank T. Kolligs, Thomas Kirchner, Burkhard Göke, Enrico N. De Toni. Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma. Clinical Cancer Research 2010; 16(22): 5529 doi: 10.1158/1078-0432.CCR-09-3403
|
| 19 |
Andres Forero‐Torres, Jeffrey R. Infante, David Waterhouse, Lucas Wong, Selwyn Vickers, Edward Arrowsmith, Aiwu Ruth He, Lowell Hart, David Trent, James Wade, Xiaoping Jin, Qiang Wang, TaShara Austin, Michael Rosen, Robert Beckman, Reinhard von Roemeling, Jonathan Greenberg, Mansoor Saleh. Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer. Cancer Medicine 2013; 2(6): 925 doi: 10.1002/cam4.137
|
| 20 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2016; : 1 doi: 10.1007/978-3-319-26587-2_176-1
|
| 21 |
Alexandra Aronin, Shira Amsili, Tatyana B. Prigozhina, Kobi Tzdaka, Jacob Rachmilewitz, Noam Shani, Mark L. Tykocinski, Michal Dranitzki Elhalel, Tetsuo Takehara. Fn14•Trail Effectively Inhibits Hepatocellular Carcinoma Growth. PLoS ONE 2013; 8(10): e77050 doi: 10.1371/journal.pone.0077050
|
| 22 |
Yukiko Saitou, Katsuya Shiraki, Hiroyuki Fuke, Tomoko Inoue, Kazumi Miyashita, Yutaka Yamanaka, Yumi Yamaguchi, Norihik Yamamoto, Keiichi Ito, Kazushi Sugimoto, Takeshi Nakano. Involvement of tumor necrosis factor–related apoptosis-inducing ligand and tumor necrosis factor–related apoptosis-inducing ligand receptors in viral hepatic diseases. Human Pathology 2005; 36(10): 1066 doi: 10.1016/j.humpath.2005.07.019
|
| 23 |
Christian Körner, Katarina Riesner, Benjamin Krämer, Marianne Eisenhardt, Andreas Glässner, Franziska Wolter, Thomas Berg, Tobias Müller, Tilman Sauerbruch, Jacob Nattermann, Ulrich Spengler, Hans Dieter Nischalke. TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients. BMC Cancer 2012; 12(1) doi: 10.1186/1471-2407-12-85
|
| 24 |
Kristin Wahl, Martin Siegemund, Frank Lehner, Florian Vondran, Andreas Nüssler, Florian Länger, Till Krech, Roland Kontermann, Michael P. Manns, Klaus Schulze-Osthoff, Klaus Pfizenmaier, Heike Bantel. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Hepatology 2013; 57(2): 625 doi: 10.1002/hep.26082
|
| 25 |
Jichun Sun, Hongbo Xu, Zhao Lei, Zhiqiang Li, Hongwei Zhu, Zhen Deng, Xiao Yu, Xiaoxin Jin, Zhi Yang. The lncRNA CASC2 Modulates Hepatocellular Carcinoma Cell Sensitivity and Resistance to TRAIL Through Apoptotic and Non-Apoptotic Signaling. Frontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.726622
|
| 26 |
Ronald Koschny, Sylvia Brost, Ulf Hinz, Jaromir Sykora, Emanuela M Batke, Stephan Singer, Kai Breuhahn, Wolfgang Stremmel, Henning Walczak, Peter Schemmer, Peter Schirmacher, Tom M Ganten. Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma. BMC Cancer 2013; 13(1) doi: 10.1186/1471-2407-13-532
|
| 27 |
Joaquim Moreno-Càceres, Isabel Fabregat. Apoptosis in liver carcinogenesis and chemotherapy. Hepatic Oncology 2015; 2(4): 381 doi: 10.2217/hep.15.27
|
| 28 |
Anita Pathil, Sorin Armeanu, Sascha Venturelli, Paolo Mascagni, Thomas S. Weiss, Michael Gregor, Ulrich M. Lauer, Michael Bitzer. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006; 43(3): 425 doi: 10.1002/hep.21054
|
| 29 |
Johanna Dzieran, James F. Beck, Jürgen Sonnemann. Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics. Cancer Science 2008; 99(8): 1685 doi: 10.1111/j.1349-7006.2008.00868.x
|
| 30 |
Wei Jiang, Dong-Bo Wu, Si-Yu Fu, En-Qiang Chen, Hong Tang, Tao-You Zhou. Insight into the role of TRAIL in liver diseases. Biomedicine & Pharmacotherapy 2019; 110: 641 doi: 10.1016/j.biopha.2018.12.004
|